drugset
drugset / Trial / NCT01808469

First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers

NCT01808469 ↗

Phase 1 Completed 80 enrolled Light Chain Bioscience - Novimmune SA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability and distribution and elimination of a novel therapeutic drug when administered to Healthy Volunteers. In addition its effects on some inflammatory parameters will be measured in presence or absence of lipopolysaccharide stimulation.

Timeline

Start
2012-11
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject paridiprubart Monoclonal antibody — Intravenous

Indications

No indication recorded.